Benjamin Djulbegovic mainly investigates Internal medicine, Randomized controlled trial, MEDLINE, Surgery and Oncology. His study in Meta-analysis, Clinical trial, Multiple myeloma, Cancer and Neutropenia are all subfields of Internal medicine. His Randomized controlled trial research includes themes of Odds ratio, Intensive care medicine and Hazard ratio, Confidence interval.
As a part of the same scientific study, Benjamin Djulbegovic usually deals with the MEDLINE, concentrating on Guideline and frequently concerns with Family medicine. His work deals with themes such as Research design and Observational study, which intersect with Oncology. In his study, Alternative medicine is strongly linked to Systematic review, which falls under the umbrella field of Evidence-based medicine.
Internal medicine, Randomized controlled trial, Oncology, Intensive care medicine and Clinical trial are his primary areas of study. Adverse effect is closely connected to Surgery in his research, which is encompassed under the umbrella topic of Internal medicine. His work is dedicated to discovering how Randomized controlled trial, Alternative medicine are connected with Family medicine and other disciplines.
His studies deal with areas such as Psychological intervention, Cancer and Disease as well as Intensive care medicine. His studies in Clinical trial integrate themes in fields like Research design and Clinical research. Benjamin Djulbegovic has researched Evidence-based medicine in several fields, including Guideline and Systematic review.
His scientific interests lie mostly in Internal medicine, MEDLINE, Evidence-based medicine, Intensive care medicine and Oncology. His studies in Meta-analysis, Randomized controlled trial, Myeloid leukemia, Hazard ratio and Zoledronic acid are all subfields of Internal medicine research. The study incorporates disciplines such as Odds ratio, Adverse effect and Confidence interval in addition to Randomized controlled trial.
His MEDLINE research is multidisciplinary, incorporating perspectives in Guideline and Sample size determination. The various areas that Benjamin Djulbegovic examines in his Evidence-based medicine study include Systematic review, Decision theory, Family medicine and Health policy. His Intensive care medicine research incorporates elements of Cancer, Hematology, Venous thromboembolism, Evidence-based practice and Disease.
His primary areas of investigation include Internal medicine, MEDLINE, Randomized controlled trial, Meta-analysis and Evidence-based medicine. He integrates many fields, such as Internal medicine and Hypomethylating agent, in his works. His MEDLINE research includes elements of Cancer, Sample size determination and Intensive care medicine.
Benjamin Djulbegovic combines subjects such as Survival analysis and Confidence interval with his study of Randomized controlled trial. His Meta-analysis research is multidisciplinary, relying on both Phase iii trials, Progression-free survival, Oncology and Daratumumab. Benjamin Djulbegovic interconnects Decision theory, Historical Article and Critical appraisal in the investigation of issues within Evidence-based medicine.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Estimating the mean and variance from the median, range, and the size of a sample.
Stela Pudar Hozo;Benjamin Djulbegovic;Iztok Hozo.
BMC Medical Research Methodology (2005)
Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group
Robert A. Kyle;J. Anthony Child;Kenneth Anderson;Bart Barlogie.
British Journal of Haematology (2003)
Pharmaceutical industry sponsorship and research outcome and quality: systematic review
Joel Lexchin;Lisa A Bero;Benjamin Djulbegovic;Otavio Clark.
Red Blood Cell Transfusion: A Clinical Practice Guideline From the AABB*
Jeffrey L. Carson;Brenda J. Grossman;Steven Kleinman;Alan T. Tinmouth.
Annals of Internal Medicine (2012)
Recommendations on the Use of 18F-FDG PET in Oncology
James W. Fletcher;James W. Fletcher;Benjamin Djulbegovic;Heloisa P. Soares;Barry A. Siegel.
The Journal of Nuclear Medicine (2008)
Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials.
John Koreth;Richard Schlenk;Kenneth J. Kopecky;Sumihisa Honda.
Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia.
Charles L. Bennett;Samuel M. Silver;Benjamin Djulbegovic;Athena T. Samaras.
Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology.
J. Douglas Rizzo;Alan E. Lichtin;Steven H. Woolf;Jerome Seidenfeld.
Multicenter Phase II Study of Bortezomib in Patients With Relapsed or Refractory Mantle Cell Lymphoma
Richard I. Fisher;Steven H. Bernstein;Brad S. Kahl;Benjamin Djulbegovic.
Journal of Clinical Oncology (2006)
Recombinant Human Erythropoietins and Cancer Patients: Updated Meta-Analysis of 57 Studies Including 9353 Patients
Julia Bohlius;Jayne Wilson;Jerome Seidenfeld;Margaret Piper.
Journal of the National Cancer Institute (2006)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: